Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial - Arnon P. Kater, Mark-David Levin, Julie Dubois, Sabina Kersting, Lisbeth Enggaard, Gerrit J. Veldhuis, Rogier Mous, Clemens H. M. Mellink, Anne-Marie F. van der Kevie-Kersemaekers, Johan A. Dobber, Christian B. Poulsen, Henrik Frederiksen, Ann Janssens, Ida Schjødt, Ellen C. Dompeling - Dissemin

Dissemin is shutting down on January 1st, 2025

Language
Login

Published in

Elsevier, The Lancet Oncology, 6(23), p. 818-828, 2022

DOI: 10.1016/s1470-2045(22)00220-0

Links

Tools

Export citation

Search in Google Scholar

Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial

Journal article published in 2022 by Arnon P. Kater, Mark-David Levin, Julie Dubois, Sabina Kersting, Lisbeth Enggaard, Gerrit J. Veldhuis, Rogier Mous, Clemens H. M. Mellink, Anne-Marie F. van der Kevie-Kersemaekers, Johan A. Dobber, Christian B. Poulsen, Henrik Frederiksen, Ann Janssens, Ida Schjødt, Ellen C. Dompeling and other authors.

This paper was not found in any repository, but could be made available legally by the author.

This paper was not found in any repository, but could be made available legally by the author.

Full text: Unavailable

Green circle

Preprint: archiving allowed

Upload

Green circle

Postprint: archiving allowed

Upload

Red circle

Published version: archiving forbidden

Policy details

Data provided by

SHERPA/RoMEO